Evidence map›Paper›PMID 37457915›Full record

ArticleCritical care explorations2023

Biomarker Signatures of Severe Acute Kidney Injury in a Critically Ill Cohort of COVID-19 and Non-COVID-19 Acute Respiratory Illness.

Neha A Sathe, Ana Mostaghim, Elizabeth Barnes, Nicholas G O'Connor, Sharon K Sahi, Sana S Sakr, Jana M Zahlan, Craig H Smith, Michael Fitzpatrick, Eric D Morrell and 2 more

Open access · goldAbstract read
In one paragraph

Article in Critical care explorations, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Plasma proteomics of acute tubular injury.Nature communications · 2024
    Article
  5. Observational
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Neha A SatheDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Ana MostaghimDepartment of Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, MD.
Elizabeth BarnesDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Nicholas G O'ConnorDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Sharon K SahiDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Sana S SakrDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Jana M ZahlanDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
Craig H SmithSepsis Center Of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA.
Michael FitzpatrickSepsis Center Of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA.
Eric D MorrellDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
W Conrad LilesSepsis Center Of Research Excellence-UW (SCORE-UW), University of Washington, Seattle, WA.
Pavan K BhatrajuDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA.
University of Washington · USNational Institutes of Health Clinical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney and lung injury are closely inter-related during acute respiratory illness, but the molecular risk factors that these organ injuries share are not well defined.

objectivesWe identified plasma biomarkers associated with severe acute kidney injury (AKI) during acute respiratory illness, and compared them to biomarkers associated with severe acute respiratory failure (ARF). DESIGN SETTINGS AND

participantsProspective observational cohort study enrolling March 2020 through May 2021, at three hospitals in a large academic health system. We analyzed 301 patients admitted to an ICU with acute respiratory illness. MAIN OUTCOMES AND MEASURES: Outcomes were ascertained between ICU admission and day 14, and included: 1) severe AKI, defined as doubling of serum creatinine or new dialysis and 2) severe ARF, which included new or persistent need for high-flow oxygen or mechanical ventilation. We measured biomarkers of immune response and endothelial function, pathways related to adverse kidney and lung outcomes, in plasma collected within 24 hours of ICU admission. Severe AKI occurred in 48 (16%), severe ARF occurred in 147 (49%), and 40 (13%) patients experienced both. Two-fold higher concentrations of soluble tumor necrosis factor receptor-1 (sTNFR-1) (adjusted relative risk [aRR], 1.56; 95% CI, 1.24-1.96) and soluble triggering receptor on myeloid cells-1 (sTREM-1) (aRR, 1.85; 95% CI, 1.42-2.41), biomarkers of innate immune activation, were associated with higher risk for severe AKI after adjustment for age, sex, COVID-19, and Acute Physiology and Chronic Health Evaluation-III. These biomarkers were not significantly associated with severe ARF. Soluble programmed cell death receptor-1 (sPDL-1), a checkpoint pathway molecule, as well as soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1), molecules involved with endothelial-vascular leukocyte adhesion, were associated with both severe AKI and ARF. CONCLUSIONS AND RELEVANCE: sTNFR-1 and sTREM-1 were linked strongly to severe AKI during respiratory illness, while sPDL-1, sICAM-1 and sVCAM-1 were associated with both severe AKI and ARF. These biomarker signatures may shed light on pathophysiology of lung-kidney interactions, and inform precision medicine strategies for identifying patients at high risk for these organ injuries.

Indexed as

acute kidney injuryacute respiratory failurebiomarkersphenotypesprecision medicine

Identifiers

PMID37457915
PMCPMC10348733
OpenAlexW4384207961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.